Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

NCT03711058 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor
Microsatellite Stable (MSS) Colon Cancer

Interventions

DRUG: Copanlisib
DRUG: Nivolumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]